Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 2
2010 1
2011 5
2012 2
2013 2
2014 1
2015 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.
Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Pappa KA, Woodward WC, Patterson K, Bolivar H, Benson CA, Collier AC; AIDS Clinical Trials Group Study A5202 Team. Daar ES, et al. Ann Intern Med. 2011 Apr 5;154(7):445-56. doi: 10.7326/0003-4819-154-7-201104050-00316. Epub 2011 Feb 14. Ann Intern Med. 2011. PMID: 21320923 Free PMC article. Clinical Trial.
Changes in metabolic syndrome status after initiation of antiretroviral therapy.
Krishnan S, Schouten JT, Atkinson B, Brown TT, Wohl DA, McComsey GA, Glesby MJ, Shikuma C, Haubrich R, Jacobson DL. Krishnan S, et al. J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):73-80. doi: 10.1097/QAI.0000000000000397. J Acquir Immune Defic Syndr. 2015. PMID: 25321179 Free PMC article.
Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239.
Marks KM, Kitch D, Chung RT, Hadigan C, Andersen J, Tien P, Luetkemeyer A, Alston-Smith B, Glesby MJ; A5239 Team. Marks KM, et al. J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):345-9. doi: 10.1097/QAI.0000000000000073. J Acquir Immune Defic Syndr. 2014. PMID: 24525470 Free PMC article. Clinical Trial.
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES; AIDS Clinical Trials Group Study A5202 Team. Sax PE, et al. N Engl J Med. 2009 Dec 3;361(23):2230-40. doi: 10.1056/NEJMoa0906768. Epub 2009 Dec 1. N Engl J Med. 2009. PMID: 19952143 Free PMC article. Clinical Trial.
Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229.
McComsey GA, Walker UA, Budhathoki CB, Su Z, Currier JS, Kosmiski L, Naini LG, Charles S, Medvik K, Aberg JA; AIDS Clinical Trials Group A5229 Team. McComsey GA, et al. AIDS. 2010 Oct 23;24(16):2507-15. doi: 10.1097/QAD.0b013e32833ea9bc. AIDS. 2010. PMID: 20827170 Free PMC article. Clinical Trial.
Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings.
Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C, Grinsztejn B, Hosseinipour MC, Kumwenda J, Lalloo U, Riviere C, Sanchez J, Melo M, Supparatpinyo K, Tripathy S, Martinez AI, Nair A, Walawander A, Moran L, Chen Y, Snowden W, Rooney JF, Uy J, Schooley RT, De Gruttola V, Hakim JG; PEARLS study team of the ACTG. Campbell TB, et al. PLoS Med. 2012;9(8):e1001290. doi: 10.1371/journal.pmed.1001290. Epub 2012 Aug 14. PLoS Med. 2012. PMID: 22936892 Free PMC article. Clinical Trial.
15 results